Bayer debuts flame-retardant PC/ABS plastic for imaging

Justine Varieur Cadet | | Health Imaging | Molecular Imaging
Bayer MaterialScience is introducing a specialty grade of resin designed for use in diagnostic imaging equipment, such as CT, MRI and PET scanners, workstations and kiosks.

Bayblend M303 FR is a nonreinforced, flame-retardant, amorphous, thermoplastic polymer blend of polycarbonate and acrylonitrile butadiene styrene copolymer (PC/ABS) for extrusion, blow molding and thermoforming, according to the Anaheim, Calif.-based company. It can be used in surface device applications contacting intact skin. Bayblend M303 FR PC/ABS meets the requirements of ISO 10993-5 (Cytotoxicity) and ISO 10993-10 (Irritation and Sensitization) guidelines.


Justine Varieur Cadet

Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.